Does imaging surveillance intensity govern clinical outcomes in HCC?May 17, 2022Hepatocellular Carcinoma
Subsequent anticancer therapy after ICI treatment prolongs survival in HCCMay 17, 2022Hepatocellular Carcinoma
Pembrolizumab monotherapy shows promise for untreated advanced HCC in phase 2May 17, 2022Hepatocellular Carcinoma
Early-stage HCC: OLT offers better survival outcomes than ablative therapies in the elderlyMay 17, 2022Hepatocellular Carcinoma
TACE vs. LR: Better prognosis in HCC with bile duct tumor thrombus?April 26, 2022Hepatocellular Carcinoma
TACE is safe and effective in elderly patients with intermediate HCCApril 26, 2022Hepatocellular Carcinoma
Tenofovir vs. entecavir: Better therapeutic in HBV-related HCC after radiofrequency ablationApril 26, 2022Hepatocellular Carcinoma
Unresectable HCC: Suboptimal response to lenvatinib plus pembrolizumab beyond the first-line settingApril 26, 2022Hepatocellular Carcinoma
Preliminary results call for evaluating AtezoBev in unresectable HCC beyond the CP-A criteriaApril 26, 2022Hepatocellular Carcinoma
Adjuvant SBRT after marginal resection: A safe therapeutic option for MVI-positive HCC April 26, 2022Hepatocellular Carcinoma
Surveillance for HCC occurrence in NAFLD: Why concentrate our efforts?April 26, 2022Hepatocellular Carcinoma
On-treatment HCC risk is inversely related to baseline viral load in HBeAg-positive chronic hepatitis BApril 26, 2022Hepatocellular Carcinoma
Aspirin use may be protective against HCC in chronic hepatitis BApril 26, 2022Hepatocellular Carcinoma
